University of Sussex to lead multi-million pound project to treat debilitating symptoms
Scientists at the University of Sussex have started work on a multi-million pound project to develop drugs to treat the debilitating loss of cognitive function associated with Huntington’s disease.
The uncontrolled movements that characterise Huntington’s disease generally appear in middle age. However, a decline in cognitive function can occur in patients 10–15 years prior to the movement disorders. This can have life-changing consequences, such as a loss of employment as well as a loss of the ability to drive.
Currently there are no drugs on the market which treat these symptoms – but now scientists from the University’s Sussex Drug Discovery Centre (SDDC) have been awarded £3m from the Wellcome Trust to develop drugs which could help to transform the lives of Huntington’s disease sufferers around the world.
Cognitive impairment in Huntington’s disease is in fact the most disabling symptom of the illness.
The SDDC team, which is a part of the University of Sussex’s School of Life Sciences, will work to identify and develop novel compounds which target a specific brain protein known as the alpha5 GABAA receptor, known to control cognitive function.
The pharmaceutical company AstraZeneca are involved in the project.
Scientists from the University of Dundee, who are also key collaborators, have previously shown that an experimental compound, called α5IA, can reverse some of the cognitive deficits observed in a mouse model of this degenerative brain disorder.
The earlier symptoms of Huntington’s disease … cause problems with multitasking, organising and planning.
John Atack from the University of Sussex said: “The earlier symptoms of Huntington’s disease, which cause problems with multitasking, organising and planning are life-changing for sufferers and often lead to them being unable to carry out everyday tasks such as working and driving.”
“By developing a drug which treats these debilitating symptoms, we can significantly improve the life quality of the patients themselves and also of their families and carers.”
We can significantly improve the life quality of the patients themselves and also of their families and carers.
Cath Stanley, Chief Executive of the Huntington's Disease Association, said: “Cognitive impairment in Huntington’s disease is in fact the most disabling symptom of the illness and brings with it devastating consequences for both the individual affected and their family.”
“Currently there is very little research carried out that involves the development of a drug to improve this part of the condition, so this research has the potential to be life-changing.”